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Data in the literature regarding the factors that predict unfavorable outcomes in adult herpetic meningoencephalitis (HME)
cases are scarce. We conducted a multicenter study in order to provide insights into the predictors of HME outcomes, with spe-
cial emphasis on the use and timing of antiviral treatment. Samples from 501 patients with molecular confirmation from cere-
brospinal fluid were included from 35 referral centers in 10 countries. Four hundred thirty-eight patients were found to be eligi-
ble for the analysis. Overall, 232 (52.9%) patients experienced unfavorable outcomes, 44 died, and 188 survived, with sequelae.
Age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02 to 1.05), Glasgow Coma Scale score (OR, 0.84; 95% CI, 0.77 to
0.93), and symptomatic periods of 2 to 7 days (OR, 1.80; 95% CI, 1.16 to 2.79) and>7 days (OR, 3.75; 95% CI, 1.72 to 8.15) until
the commencement of treatment predicted unfavorable outcomes. The outcome in HME patients is related to a combination of
therapeutic and host factors. This study suggests that rapid diagnosis and early administration of antiviral treatment in HME
patients are keys to a favorable outcome.
Encephalitis due to herpes simplex virus (HSV) is the most fre-quent form of sporadic fatal encephalitis in the world and ac-
counts for 10 to 20% of all viral encephalitis cases worldwide (1–3).
The annual incidence for herpetic meningoencephalitis (HME) is
around 0.2 to 0.4 adults per 100,000 (4). In addition, patients with
HME experience exceedingly high unfavorable outcomes, including
death and long-term sequelae, despite treatment (5–8).
Previous studies (9, 10) have assessed outcomes, in particular
by comparing the efficacies of herpetic antiviral drugs. To the best
of our knowledge, data thoroughly assessing the predictors of un-
favorable outcome in HME patients do not exist in the literature.
One more potential limitation of the studies published was that
they included cases without virological confirmation (11–13),
thus blurring the inferences made. Hence, in this multinational
study, we included only HME patients with a definite virological
diagnosis. Consequently, our study makes use of data from the
largest case series ever reported in the literature to determine the
predictors of unfavorable outcome in HME.
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MATERIALS AND METHODS
Study design. This retrospective multicenter study included hospitalized
patients from referral centers in 10 countries (Croatia, the Czech Repub-
lic, Denmark, Egypt, France, Iraq, Italy, Lebanon, Slovenia, and Turkey)
between 2000 and 2013. Only adult patients (15 years of age) with HME
were included. No control groups were included for this study. The insti-
tutional review board of the Dr. Lütfi Kirdar Training and Research Hos-
pital in Istanbul, Turkey, approved the study, which was exempt from the
requirement for informed patient consent.
The inclusion criteria comprised both of the following: (i) positive
cerebrospinal fluid (CSF)-PCR result for herpes simplex virus 1 (HSV-1),
HSV-2, or both in a patient with meningoencephalitis and (ii) the unlikely
presence of any other infectious disease of the brain.
Definitions. Meningoencephalitis was defined as a clinical, radiolog-
ical, and/or laboratory presentation compatible with encephalitis (3, 8,
14) and meningitis (1, 15). The clinical findings related to encephalitis
mainly included changes in consciousness and/or language, behavioral
abnormalities, memory impairment, and seizures. The magnetic reso-
nance imaging, electrophysiological studies, and/or CSF analysis data
were used to provide clues regarding the encephalitic component of the
disease (3). Meningitis was identified by the presence of an abnormal
number of leukocytes in the CSF, along with compatible clinical findings,
like fever, headache, meningism, cranial nerve palsies, or altered con-
sciousness (16). Unfavorable outcome was defined as patients who died of
HME or survived with sequelae. New-onset convulsion was defined as a
convulsion observed between the onset of symptoms and the start of an-
tiviral treatment for HME. Immunosuppression was defined as a patient
who was under a long-term steroid treatment or had a disease(s) causing
immunosuppression, such as malignancy, autoimmune disease, or diabe-
tes. Motor symptoms were defined as locomotor deficiency, paresis, tet-
raparesis, hemiparesis, quadriparesis, quadriplegia, spasticity, left foot
drop, or disrupted motoric skills.
Statistical analysis. Statistics were done using the software package
Stata 13.1 (StataCorp, TX, USA). In the univariate analysis, categorical
variables were compared by Pearson’s chi-square test and where applica-
ble by Fisher’s exact test. Continuous variables were compared by Stu-
dent’s t test or by the Wilcoxon rank-sum test, depending on the normal-
ity assumption for which the Shapiro-Wilk and Shapiro-Francia tests
were used.
A total of 3% (15/438) of the observations were missing. The pat-
tern of missingness indicated this as “missing completely at random.”
Therefore, missing observations were not filled via a multiple imputa-
tion procedure.
A binary logistic regression model was constructed via a bootstrap
resampling procedure described in detail elsewhere (17). Briefly, the data
set was replaced by resampling 200 times during the logistic regression
analysis of the full model, consisting of all potential variables. Eventually,
variables with frequencies of 30% of the bootstrapped data sets with a
0.1 significance threshold were included in the final model. The final
model was tested with logistic regression, including all possible interac-
tion terms. Colinearity was also tested and eliminated.
RESULTS
In this study, data from 501 HME patients were submitted from 35
referral centers in 10 countries (Turkey [n 144], Denmark [n
127], France [n  64], Slovenia [n  54], Croatia [n  32], Iraq
[n 30], the Czech Republic [n 23], Italy [n 12], Lebanon [n
 8], and Egypt [n 7]). Sixty-three patients were excluded, due
to either missing critical data or the absence of molecular confir-
mation, leaving 438 patients eligible for outcome analysis. HSV-
1/2 PCR was found to be positive in 105 patients. HSV-1 DNA was
positive in 300 cases, and HSV-2 DNA was positive in 79 cases. A
brain biopsy was not performed in any of the patients. In this
study, 375 (85.6%) patients received intravenous aciclovir, and in
53 (12.1%) cases, oral valaciclovir was given following intrave-
nous aciclovir treatment. Nine cases were treated with valaciclo-
vir. Finally, one case received intravenous ganciclovir following
intravenous aciclovir. The mean standard deviation (SD) treat-
ment duration of the aciclovir-only arm was 21.6  12.3 days,
while valaciclovir alone was given for a mean SD of 10.3 4.6
days. In the group receiving intravenous aciclovir followed by oral
valaciclovir, the drugs were given for 15.5 10.7 and 32.7 18.9
days, respectively. The mean  SD dose of intravenous aciclovir
was 36.7  5.7 mg/kg of body weight/day. In this study, 232
(52.9%) patients experienced unfavorable outcomes. Forty-four
HME patients died, and 188 survivors of the disease had experi-
enced sequelae at the end of antiviral treatment. Overall, there
were 313 disorders attributed to HME in 188 patients with se-
quelae. Memory disorder (n 62), behavioral disorders (n 55),
speech impairment (n 53), motor symptoms (n 40), epilepsy
(n  34), cognitive impairment (n  29), headache (n  13),
psychiatric disorders (n  10), balance disorder (n  6), and
visual disturbances (n  5) were the frequent unfavorable out-
comes. Tinnitus, sleeping disorder, coma, autoimmune encepha-
litis, neurogenic bladder, and autonomy loss were seen in a single
case each.
The baseline characteristics of the study group are presented in
Table 1. Briefly, the study group consisted of patients with a mean
TABLE 1 Baseline characteristics
Variable Dataa
Age (mean SD) (yr) 50.58 18.27
Gender
Women 226 (51.6)
Men 212 (48.4)
Elapsed time between OS & AVT (days)b
2 195 (44.5)
2 and7 191 (43.6)
7 47 (10.7)
Missing data 5 (1.1)
Glasgow Coma Scale score (median [IQR]) 14 (13–15)
New-onset convulsionc
No 343 (78.3)
Yes 91 (20.8)
Missing data 4 (0.9)
Immunosuppressiond
No 379 (86.5)
Yes 59 (13.5)
Outcome
Favorable 206 (47.0)
Unfavorable 232 (53.0)
Died 44 (10.0)
Survived with severe sequela(e) 188 (42.9)
a Values are no. (%) of patients, unless otherwise indicated. Total n 438.
b Elapsed time between onset of symptoms (OS) and the start of antiviral treatment
(AVT).
c Defined as a convulsion observed before therapy.
d Defined as long-term steroid use or other immunosuppressive state.
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( SD) age of 50.6 ( 18.3) years, and 48.4% (212/438) were of
the male gender. Almost half of the patients (44.5% [195/438])
received antiviral treatment during the first 2 days after the onset
of symptoms. The median elapsed time between the onset of
symptoms and antiviral treatment was 3 days (interquartile range
[IQR], 1 to 5 days). In this study, 10% (44/438) died, while 42.9%
(188/438) survived with severe sequelae. A univariate comparison
of the variables between the patients with favorable and unfavor-
able outcomes is presented in Table 2. Age, male gender, longer
time gap between the onset of symptoms and antiviral treatment,
lower Glasgow Coma Scale (GCS) scores, and convulsion were
significantly different in the patients with unfavorable outcomes
compared to those in the patients with favorable outcomes.
Among these, however, only age, GCS score, and time to antiviral
treatment were included in the final model (Table 3).
This multivariate model found that a delay in establishing
an effective antiviral treatment significantly increases the risk
of unfavorable outcome. Accordingly, a delay of 7 days
causes a significant increase in unfavorable outcome among
patients. This is documented by the multivariate model, in
which the odds ratio for a delay in the onset of aciclovir treat-
ment of7 days being 3.75 (95% confidence interval [CI], 1.72
to 8.15) and that for 2 to 7 days being 1.80 (95% CI, 1.16 to
2.79) are significant, whereas the odds ratio for 2 days being
0.48 (95% CI, 0.32 to 0.74; P  0.001) is protective (estimates
made by univariate logistic regression).
The predicted percentages of unfavorable outcome versus
elapsed time since the onset of symptoms are presented in Fig. 1,
where unfavorable outcome increases from 0.44 to 0.71 depend-
ing on the delay in establishing an effective antiviral treatment.
The observed outcomes against the predicted outcomes estimated
by the logistic regression analysis were in perfect agreement
(Fig. 2).
The multivariate model documented that age and GCS score
independently predict unfavorable outcome. The relationship be-
tween these and outcome is shown in Fig. 3. Briefly, unfavorable
outcome was more frequent with increasing age, at80% among
the geriatric patients. An interaction between age and male gender
was also found, indicating that elderly males experienced more
unfavorable outcomes. Lower GCS scores were found to be asso-
ciated with more unfavorable outcome, at80% in patients with
scores lower than five.
DISCUSSION
There are a number of published reports with relatively small case
series assessing unfavorable outcome in HME. Advanced age (10,
18, 19), lower GCS score (10), greater extent of brain involvement
(20, 21), low serum albumin level (18), longer duration of disease
(20), delayed aciclovir use (18, 19, 21–24), the presence of red
blood cells in the CSF (19), and immunosuppression (24) have
been found to be associated with poorer outcomes in HME. In this
study, we detected that a combination of therapeutic and host
factors contributed to the outcomes in HME patients. Advancing
age, delayed start of antivirals, and worsening of consciousness
determined by the GCS contributed to the development of unfa-
vorable outcomes in these patients. In a relatively large study by
Raschilas (22), higher Simplified Acute Physiology Score II and a
delay in the initiation of antiviral therapy were associated with
TABLE 2 Comparison of variables among patients with favorable and
unfavorable outcomes
Variable
Data for outcome ofa:
P valueFavorable Unfavorable
Age (mean SD) (yr) 44.50 16.80 55.97 17.86 0.001
Gender 0.005
Women 121 (58.7) 105 (45.3)
Men 85 (41.3) 127 (54.7)
Elapsed time between OS
& AVT (days)b
0.001
2 113 (55.7) 82 (35.7)
2 and7 78 (38.4) 113 (49.1)
7 12 (5.9) 35 (15.2)
Glasgow Coma Scale score
(mean SD)
13.80 2.15 12.57 3.05 0.001
New-onset convulsionc 31 (15.1) 60 (26.2) 0.005
Immunosuppressiond 24 (11.7) 35 (15.1) 0.29
a Values are no. (%) of patients, unless otherwise indicated.
b Elapsed time between onset of symptoms (OS) and the start of antiviral treatment
(AVT).
c Defined as a convulsion observed before therapy.
d Defined as long-term steroid use or other immunosuppressive state.
TABLE 3 Final model, including independent predictors of unfavorable
outcome
Variable ORa
95% CI
PLow High
Age (yr) 1.04 1.02 1.05 0.000
Glasgow Coma Scale score 0.84 0.77 0.93 0.000
Elapsed time (days)b
2 and7 1.80 1.16 2.79 0.009
7 3.75 1.72 8.15 0.001
a OR, odds ratio.
b Elapsed time between onset of symptoms and administration of antiviral treatment.
FIG 1 Predictions (Pr, probability) of antiviral treatment timing for unfavor-
able outcome. The data are presented as the mean values with the 95% CI.
Erdem et al.
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poor prognosis. These results are quite in accordance with those of
this study. On the other hand, the data in the literature related to
the efficacy of treatment in HSV-2 meningitis are rather unclear
(25, 26).The host parameters directly affect the course of central
nervous system (CNS) infections. In different types of CNS infec-
tions, increasing age and lower GCS scores have long been known
to be associated with poor outcomes (27–29). Our HME data were
also in accordance with those regarding other infectious CNS dis-
orders and with the initial reports of adult HME series (10, 18, 19).
According to our results, patients with a GCS score of less than five
experienced unfavorable outcome more frequently. Added to
that, older males were more likely than were others to have unfa-
vorable outcomes from HME. Convulsions are also believed to
occur in patients with poor outcomes (30). In this study, we did
not determine a significant relationship between new-onset con-
vulsions and poor outcome in HME patients.
In daily medical practice, the use of aciclovir at standard dos-
ages has been reported to be of paramount importance in HME
patients (1, 3, 8). However, the importance of the optimal timing
of aciclovir administration in the improvement of outcomes has
been unclear. Added to that, the benefit of the empirical use of
aciclovir in patients with a likely diagnosis of encephalitis, rather
than in those with confirmed HSV encephalitis, has not yet been
proven in a randomized controlled clinical trial (1). In a previous
study (31), 17 out of 24 (71%) of patients with suspected enceph-
alitis did not receive empirical aciclovir in the emergency depart-
ment but rather after inpatient admission (median time, 16 h;
95% CI, 7.5 to 44 h). In this study, three of five confirmed HSV
encephalitis cases were not given aciclovir in the emergency de-
partment (31). In a large previous study (22), a mean SD delay
of 5.5 2.9 days elapsed between the onset of symptoms and the
initiation of antiviral treatment. These data indicate that an early
start to antiviral treatment in HME patients is not likely. This
study suggests that aciclovir administered within the first 2 days
after the onset of symptoms significantly contributed to better
outcomes. The goal of empirical antiviral treatment is to improve
the prognoses in patients who are ultimately proven to have HME.
Thus, suspected encephalitis patients should urgently be given
FIG 2 Observed outcomes against predicted outcomes estimated by the
model.
FIG 3 Predictive margins of age and Glasgow Coma Scale score on unfavorable outcome. The data are presented as the mean values with the 95% CI.
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antiviral treatment when the results of diagnostic studies are
pending.
Although it would be very difficult to prospectively provide
such a large cohort, the major limitation of this study is its retro-
spective design. The discrimination between pure meningitis and
pure encephalitis is very difficult in a retrospective study, since
they have been known to be two interrelated syndromes with quite
similar clinical presentations; thus, we cautiously erred in favor of
not discriminating between these two diseases. On the other hand,
the major problem was the microbiological confirmation of HSV
cases due to diagnostic difficulties in previous studies (32, 33).
Since PCR testing in the CSF has an overall sensitivity and speci-
ficity of95% with HME (8), we view the inclusion of only CSF-
PCR-positive cases to be a strength of the study. Added to that, the
predicted and observed probabilities of the final model in this
study were in perfect agreement.
In conclusion, the outcome in HME patients is directly related
to both therapeutic and host factors. Host factors, like age, gender,
unconsciousness, and seizures, detected during initial evaluation,
as well as coexistent immunosuppressive conditions, may not be
preventable for the treating clinician. However, the major con-
cerns should be both the rapid diagnosis and early start to antiviral
treatment in either suspected or proven HME cases.
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